Agilent Technologies, Inc. reported a net revenue of $6.948 billion for the fiscal year ending October 31, 2025, marking a 7% increase from $6.510 billion in 2024. The growth was driven by all business segments, with the Life Sciences and Diagnostics Markets segment experiencing an 11% increase in revenue, attributed to strong performance in the pharmaceutical market and contributions from the recent acquisition of BIOVECTRA, which added approximately 5 percentage points to revenue growth. In contrast, the Applied Markets segment saw a modest 1% increase, while the Agilent CrossLab segment grew by 6%. The overall impact of foreign currency movements on revenue was negligible.
In terms of profitability, Agilent's net income rose to $1.303 billion in 2025, up from $1.289 billion in 2024. This increase was supported by tax benefits that reduced the overall tax provision. The company’s operating margin decreased slightly to 21.3% from 22.9% in the previous year, influenced by higher tariffs, shipping costs, and increased variable pay, although these were partially offset by higher sales volume and targeted pricing increases. The total gross margin also fell to 52.4% from 54.3% in 2024, reflecting similar pressures.
Strategically, Agilent underwent a significant organizational restructuring in November 2024, consolidating its segments into three main areas: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This reorganization aims to enhance customer focus and operational efficiency. The company also completed the acquisition of BIOVECTRA for $915 million, which is expected to bolster its contract development and manufacturing capabilities.
Operationally, Agilent employed approximately 18,100 people as of October 31, 2025, a slight increase from 17,900 in the previous year. The company served around 22,200 customers in its Life Sciences and Diagnostics Markets segment and approximately 59,700 customers in the Agilent CrossLab segment. The company reported a total of 3.4 million shares repurchased for $425 million during the fiscal year, reflecting its commitment to returning value to shareholders.
Looking ahead, Agilent remains optimistic about long-term growth opportunities across its key markets, particularly in life sciences and diagnostics. The company plans to continue investing in research and development, enhancing its applications and solutions portfolio, and expanding its presence in emerging markets. Despite recent tariff changes impacting costs, Agilent expects to mitigate these effects in fiscal year 2026 through supply chain optimization and targeted pricing actions.
About AGILENT TECHNOLOGIES, INC.
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, offering instruments, software, services, and consumables for laboratory workflows. With a focus on enhancing customer outcomes, Agilent targets pharmaceutical, biopharmaceutical, and academic sectors, addressing a $60 billion market opportunity. The company is innovating through advanced manufacturing partnerships and expanding its diagnostics and genomics capabilities, including cell analysis and companion diagnostics, to meet evolving healthcare needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.